Oral and dental care and treatment protocols for the management of HIV-infected patients.
This paper describes the workings of the workshop dedicated to oral and dental care and treatment protocols for the management of HIV-infected patients. The questions addressed were: 1) What are the current ethical issues in dental care of HIV patients, do they need to be addressed? 2) Do we need to modify the dental care we give HIV-positive patients? 3) When is it necessary to give antibiotic prophylaxis to HIV-positive patients? 4) What is the evidence for the effective treatment of oral lesions associated with HIV? 5) What is the most successful palliative treatment for KS? 6) Can we provide clinical treatment that has a scientific basis rather being trial based? 7) Is ddI + hydroxy-urea an effective African alternative to HAART? 8) What is the influence of protease inhibitors and HAART on the excretion of HIV in saliva? 9) What is the effect of anti-HIV therapy on the oral mucosa and oral health? This workshop did not fully cover the issue of ddI and hydroxy-urea as an alternative HIV therapy as this was considered to be the remit of general physicians caring for patients with HIV and AIDS rather than that of oral health care workers.
Shirlaw
P J
PJ
Department of Oral Medicine and Pathology, Guy's Hospital, London, UK. pepe.shirlaw@kcl.ac.uk
Chikte
U
U
MacPhail
L
L
Schmidt-Westhausen
A
A
Croser
D
D
Reichart
P
P
D017088:AIDS-Related Opportunistic Infections / Q000628:therapy; D019380:Anti-HIV Agents; D019072:Antibiotic Prophylaxis; D023241:Antiretroviral Therapy, Highly Active; D002985:Clinical Protocols; D017742:Dental Care for Chronically Ill; D016049:Didanosine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004990:Ethics, Dental; D006678:HIV / Q000502:physiology; D015658:HIV Infections; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D009059:Mouth Diseases / Q000628:therapy; D009061:Mouth Mucosa / Q000187:drug effects; D009062:Mouth Neoplasms / Q000628:therapy; D010166:Palliative Care; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012463:Saliva / Q000821:virology; D012514:Sarcoma, Kaposi / Q000628:therapy
D019380:Anti-HIV Agents; D004791:Enzyme Inhibitors; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine; D006918:Hydroxyurea